Home > Boards > US OTC > Biotechs >

Q BioMed Inc. (QBIO)

Add QBIO Price Alert      Hide Sticky   Hide Intro
Moderator: budfoxhub, StockHighAlert-
Search This Board: 
Last Post: 4/11/2019 12:10:27 AM - Followers: 22 - Board type: Free - Posts Today: 0

Q Biomed Inc.

Welcome to Q

Q BioMed Inc. is a biomedical acceleration and development company. We are dedicated to acquiring and providing strategic resources and expansion capital to innovative healthcare companies that strive to provide much needed healthcare and related products to patients in need. By partnering with exceptional entrepreneurs we aim to help to create market-leading products and companies in the biomedical and healthcare sector. As entrepreneurs and investors with operational and technical expertise we embrace a collaborative approach to capital formation and business development.

Why Q BioMed

Through Q BioMed investors have the opportunity to invest in some of the most innovative bio-medical products that they may never have known about. Technologies are vetted by analysts, industry KOLs and experts. Your investment is in Q BioMed  – so you have public company liquidity without being tied up in a private company with an unknown exit strategy and uncertain value inflection milestones (FDA etc).

Q BioMed aims to mitigate risk by having multiple relationships and assets across a broad spectrum of healthcare companies and sectors. Success being shared as multiple assets mature at different times in their development cycle passing on value to the Q BioMed shareholders.


Q has the ability to fund and/or acquire promising BioMedical assets. We use management’s expertise and network of experts to evaluate undervalued assets and to secure an equity interest in promising technologies and products. We help develop them into high value businesses. Q and its investors will benefit from early positioning in largely illiquid and unknown private assets with multiple potential products and their development cycle and valuation growth as they move forward. By structuring the company to keep overhead to a minimum and costs down there is limited burn and significant upside potential as assets progress through their development cycle.


Q BioMed Inc is assessing multiple BioMedical assets in various areas of healthcare and drug development. Our Pipeline is not complete and not yet formalized. We are actively pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates that we believe will provide a robust technology platform from which to build significant value.

Management and Directors

Denis D Corin - President and DirectorMr. Denis D. Corin is our President and a director. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental is building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also serves as a Management Consultant to the executives and board of TapImmune Inc., a clinical stage immune-oncology company where had previously served as CEO and President. He has been a Director of Q BioMed, Inc. since April 2015. He served as a Director of TapImmune Inc., from July 2009 to May 2012. He continues to serve as a Director of Soloro Gold and NPX Metals Inc. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.

William Rosenstadt - General and Corporate Securities Counsel and DirectorWilliam Rosenstadt is the founding and managing partner of Sanders Ortoli Vaughn-Flam Rosenstadt LLP an international law firm located in New York and has been a practicing attorney since 1995. William advises entrepreneurs, public companies, and other corporate entities with respect to the execution of complex commercial, corporate, and international transactions. William often serves as general counsel to his clients advising them with respect to public and private financings (equity and debt), federal securities law compliance and other merger and acquisition related transactions. Mr. Rosenstadt and his firm are authorized to sponsor issuers on the OTC Markets as Principal American Liaisons (“PAL”) and Designated Advisors for Disclosure (“DAD”) and were instrumental in introducing the Canadian Securities Exchange to the OTC Markets and having it designated as an authorized exchange. Early in his legal career, Mr. Rosenstadt was general counsel to American Industrial Acquisition Corporation, a private equity firm focused on investing in privately held, middle market manufacturers in the wire/cable and defense industries. Mr. Rosenstadt graduated from Syracuse University with a B.A. in 1990 and received his J.D. from the Benjamin N. Cardozo School of Law in 1995. Further, he is admitted to the bars of New York, New Jersey, and Connecticut as well as the Second Circuit of the federal courts of the United States.

Ari Jatwes - Corporate Advisor and Senior Analyst - Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his tremendous experience in mergers and acquisitions. Over the last decade Ari’s interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs. Ari has played an integral role in several successful contracts and transactions in the healthcare space - with emphasis on the life sciences and immunotherapy. Mr. Jatwes holds two Master degrees and a Bachelor Degree from the University of South Africa and the University of Natal.

David Laskow-Pooley - VP Scientific & Product Development - Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life technologies, OSI, Bilcare and Surface Therapeutics.

Capital Structure

Shares Issued: 9,250,000

Management/Insider Ownership: 3,2 M (35%)

Warrants: 1,000,000

Authorized: 250,000,000 Common, 100,000,000 Preferred

Q Biomed Inc.

Q Biomed Inc.
A Biotechnology Acceleration Company

501 Madison Ave, 14th Floor
New York, NY 10022
Phone: +1 (888) 357-2435
Email: info@qbiomed.com

Website: www.qbiomed.com


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
QBIO News: Quarterly Report (10-q) 04/17/2019 10:36:51 AM
QBIO News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 04/16/2019 12:47:25 PM
QBIO News: GDET CEO Interviewed By Goldman Small Cap Research On New Cannabis Business 03/19/2019 11:20:44 AM
QBIO News: Annual Report (10-k) 03/07/2019 01:16:21 PM
QBIO News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/01/2019 02:19:28 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#720   More good news coming 247MarketAddict 04/11/19 12:10:26 AM
#719   Anyone awake here 247MarketAddict 04/11/19 12:09:58 AM
#718   $QBIO Biotechnology Accelerator Positions Multiple Shots on Goal in deri21 03/27/19 10:12:26 AM
#717   Loaded and holding. Hopefully this healthy momentum keeps up! StockHighAlert- 03/22/19 02:04:08 PM
#716   $QBIO Gonna be an interesting week next week! StockHighAlert- 03/22/19 01:24:23 PM
#715   $QBIO Q BioMed’s Diagnostic Kit Designed to StockHighAlert- 03/22/19 01:11:33 PM
#714   $QBIO To Develop Revolutionary Product for Glaucoma Market StockHighAlert- 03/22/19 01:09:48 PM
#713   Enter Big Pharma StockHighAlert- 03/22/19 01:05:49 PM
#712   Q BioMed (QBIO) and its key technology partners StockHighAlert- 03/22/19 01:05:21 PM
#711   $QBIO Q BioMed's Industry-Changing Diagnostic Kit To Serve StockHighAlert- 03/22/19 01:05:09 PM
#710   NICE VIDEO Q BioMed Inc $QBIO [yt]7VX0svFbi-4[/yt] StockHighAlert- 03/22/19 01:03:15 PM
#709   $QBIO Over 70 million people suffer from glaucoma 247MarketAddict 03/21/19 08:43:20 PM
#708   Pending FDA clearance, which could come sooner than budfoxhub 03/21/19 03:04:51 PM
#707   Indeed it is Bud. Let's Roll 03/21/19 02:31:33 PM
#706   Thin to 2's heading into power hour! budfoxhub 03/21/19 02:15:33 PM
#705   $QBIO's Diagnostic Kit Designed to Serve Unmet Need BohemianRhapsody 03/21/19 01:41:53 PM
#704   $QBIO Q BioMed and Mannin Research to Develop BohemianRhapsody 03/21/19 01:41:15 PM
#703   $QBIO Goldman Small Cap Research - Company Spotlight BohemianRhapsody 03/21/19 01:40:49 PM
#702   Large volume day. Hopefully we see a bounce Seeking Alphaville 03/21/19 01:28:45 PM
#701   Q BioMed's Diagnostic Kit Designed to Serve Unmet Whos_Who 03/21/19 12:10:01 PM
#700   The QBIO product roadmap provides key insight into Seeking Alphaville 03/21/19 11:41:37 AM
#699   Things are really coming together for QBIO Seeking Alphaville 03/21/19 11:41:20 AM
#698   must read news here: https://finance.yahoo.com/news/q-biomeds-industry-changing- budfoxhub 03/21/19 10:38:09 AM
#697   2's super thin! budfoxhub 03/21/19 10:37:42 AM
#696   This is great news. QBIO is coming alive Seeking Alphaville 03/21/19 10:15:41 AM
#695   In the press release, QBIO details the next Seeking Alphaville 03/21/19 10:14:53 AM
#694   Nice day here so far. Let's see QBIO Seeking Alphaville 03/21/19 09:56:29 AM
#693   $QBIO Exclusive Interview With Chairman and CEO Denis jedijazz 03/21/19 09:55:51 AM
#692   The Biointerfaces Institute will work with Mannin Research Let's Roll 03/21/19 09:37:01 AM
#691   The Biointerfaces Institute will work with Mannin Research Let's Roll 03/21/19 09:36:03 AM
#690   The aim is to develop a simple integrated Let's Roll 03/21/19 09:35:24 AM
#689   This enabling technology will act as a companion Let's Roll 03/21/19 09:34:59 AM
#688   As a result, the GDF15-based tool could emerge Let's Roll 03/21/19 09:34:34 AM
#687   very impressive news! Seeking Alphaville 03/21/19 09:29:42 AM
#686   Ready to run! budfoxhub 03/21/19 09:29:33 AM
#685   This diagnostics kit from QBIO could be a Seeking Alphaville 03/21/19 09:29:31 AM
#684   QBIO on the breakout boards with news! Seeking Alphaville 03/21/19 09:26:06 AM
#683   This is huge for QBIO - Based on jedijazz 03/21/19 09:21:00 AM
#682   Nice news out on the Diagnostics Kit from jedijazz 03/21/19 09:20:42 AM
#681   NEW YORK, NY / ACCESSWIRE / March 21, jedijazz 03/21/19 09:20:28 AM
#680   Link to QBIO news on yahoo: https://finance.yahoo.com/news/q-biomeds-industry-ch jedijazz 03/21/19 09:20:07 AM
#679   Nice QBIO news out! Q BioMed's Industry-Changing Diagnostic jedijazz 03/21/19 09:19:45 AM
#678   2.05's thin on the ask! budfoxhub 03/21/19 09:16:58 AM
#677   Nice! should be a great day for QBIO Seeking Alphaville 03/21/19 09:13:05 AM
#676   Nice QBIO news! While this may be the Seeking Alphaville 03/21/19 09:12:37 AM
#675   $QBIO News: https://finance.yahoo.com/news/q-biomeds-industry-changing-diagnosti jedijazz 03/21/19 09:08:08 AM
#674   Glaucoma, which afflicts 70 million people, is diagnosed jedijazz 03/21/19 09:07:47 AM
#673   QBIO's prospective offering serves an unmet need for jedijazz 03/21/19 09:07:33 AM
#672   Much of the work in the Biointerfaces Institute jedijazz 03/21/19 09:07:15 AM
#671   These biosurface properties are important in materials designed jedijazz 03/21/19 09:07:05 AM